bioecon Member area
Technology · Bioproduction & equipment / Analytics & PAT

Sterility testing systems

Membrane-filtration pump systems, automated colony-detection platforms and rapid microbial detection instruments that confirm a parenteral product is free of viable microorganisms before release — a mandatory 14-day compendial test now increasingly compressed to hours or days by validated rapid alternative methods.

Manufacturing Integration & TICs Risk: low Bioprocess equipment US · CN · EU Science: why it works → verified 2026-08-11 · 5 Sources (0 independent)

1 · What it gives

Sterility testing confirms that a parenteral drug product, biologic or medical device is free of viable bacteria and fungi before it can be released to patients. The compendial reference method under USP <71> and Ph. Eur. 2.6.1 filters the sample through a membrane, incubates the membrane in growth media for 14 days, and checks for turbidity or visible growth — a proven but slow gate that can hold a finished batch in quarantine for two full weeks. Membrane-filtration pump systems automate the aseptic filtration and rinsing steps of this classical method, reducing operator handling and cross-contamination risk without changing the underlying 14-day incubation timeline. A newer generation of rapid microbial methods (RMM) — automated colony detection, ATP bioluminescence, and other growth-based or metabolic-activity techniques recognized under USP <1223> and Ph. Eur. 5.1.6 — compresses detection from 14 days to as little as a few days by automating colony counting and flagging growth earlier in the incubation curve, without changing the underlying biology being tested. The choice between classical membrane filtration and a validated rapid method is increasingly a release-speed decision as much as a technical one, since both routes must demonstrate equivalent sensitivity before regulatory acceptance.

The key directions of sterility testing are:

  1. Automated membrane-filtration pump systems (Membrane Filtration): peristaltic pump platforms that automate aseptic filtration and rinsing for the classical 14-day compendial sterility test, reducing manual handling risk.
  2. Rapid microbial detection (RMM): growth-based or metabolic-activity methods that compress sterility or bioburden detection from 14 days toward hours or a few days, validated under USP <1223> and Ph. Eur. 5.1.6.
  3. Automated colony detection platforms (Automated Colony Detection): imaging systems that continuously scan growth media and flag microbial colonies as they form, cutting incubation-to-result time versus manual end-point reading.
  4. Automated blood-culture-derived microbial detection systems (Continuous Monitoring Systems): platforms adapted from clinical blood-culture technology to continuously monitor pharmaceutical samples for microbial growth signals.

Sectoral value chain#

[Sample: drug product/device] ──> [Aseptic filtration/inoculation] ──> [Incubation: classical 14-day or RMM] ──> [Growth detection: visual/imaging/metabolic]
                                                                  │
                                                          (result vs. specification)
                                                                  │
                                                                  ▼
[Batch release / rejection] <─── [Software: colony imaging, growth-curve analysis]

Value chain levels#

LevelDescriptionKey inputs/outputs
Sample preparationThe drug product or device is prepared for aseptic transfer, and the test volume is determined per USP <71> sampling requirements.In: raw drug product/device. Out: sample ready for aseptic filtration or direct inoculation.
Aseptic filtration/inoculationA membrane-filtration pump system filters and rinses the sample, or the sample is directly inoculated into growth media.In: prepared sample. Out: filtered membrane or inoculated media, ready for incubation.
IncubationThe membrane or inoculated media incubates for 14 days (classical) or a shorter validated period (RMM) at controlled temperature.In: filtered membrane/inoculated media. Out: incubated sample showing growth or no growth.
Growth detectionVisual turbidity inspection, automated colony imaging, or a metabolic-activity/bioluminescence signal indicates the presence or absence of viable organisms.In: incubated sample. Out: growth/no-growth signal, colony count if applicable.
Software: result interpretationImaging or growth-curve software confirms detected colonies meet the assay’s positive criteria and rules out false positives from artifacts.In: raw growth-detection signal. Out: confirmed sterile/non-sterile determination.
Batch release/rejectionThe confirmed result is compared against the product’s sterility specification.In: confirmed determination. Out: batch-release or batch-rejection decision.

Cross-cutting technologies of the sector:

  • Isolator and RABS integration: sterility-testing pump systems are increasingly installed inside isolators or restricted-access barrier systems (RABS) rather than open cleanrooms, cutting false-positive risk from environmental contamination during the test itself.
  • Connected-lab digital workflows: newer pump generations add digital connectivity for direct data capture and 21 CFR Part 11-compliant audit trails, replacing paper logbooks for the aseptic filtration step.
  • Comprehensive organism panels for RMM validation: rapid-method validation increasingly relies on standardized panels of compendial and environmental organisms to demonstrate detection sensitivity equivalent to the classical 14-day method.

2 · What it replaces 3 · matched by industry

3 · How to implement 6 steps

  1. 1
    Sample preparationFormulation & blending
    The drug product or device sample volume is determined per USP <71> sampling requirements, and the sample is staged for aseptic transfer into the test system.
    Who can do this step matched automatically
    ✓ ISO 9001 500 m3
    “This is a satellite blending, mixing and formulation facility, located at Vashind near Shahapur and dedicated to the company’s Animal Nutrition business.”
    SyAqua Group Thailand
    “vannamei genetics (broodstock, nauplii, and post-larvae) built on genomic selection/marker-assisted selection plus quantitative genetics (BLUP), with disease resistance screening …”
    “In 2025-2026, it reports commissioning/stabilising Kakinada phosphoric and sulphuric acid plants (backward integration), brownfield granulation expansion progressing for completion …”
  2. 2
    Aseptic filtrationPurification & downstream
    A membrane-filtration pump system filters the sample through a sterilizing-grade membrane and rinses it with sterile diluent, or the sample is directly inoculated into growth media for smaller-volume or non-filterable products.
    Who can do this step matched automatically
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “Adherent cell culture and downstream processing: commercialized Tide Motion bioreactor platform (MiniTide to TideXcell) with closed automated cell harvesting and single-use …”
    ✓ ISO 9001 500 m3
    “Development of robust, scalable fermentation and downstream processing (production and recovery/yield optimization).”
    150 m3/month
    “We have set up a state of art laboratory at our plant including Auto Fermentor’s, Bio- digesters, Spray Driers, Aseptic blenders & computerized auto lines etc.”
    industrial scale
    “With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”
    SilicoBio South Korea
    industrial scale
    “SilicoBio is a privately held KAIST faculty startup (South Korea) developing precision-fermentation cell factory platforms to scale microbial foods and functional ingredients …”
  3. 3
    IncubationFermentation & cultivation
    The filtered membrane or inoculated media incubates at controlled temperature — 14 days for the classical compendial method, or a shorter validated period for a recognized rapid microbial method.
    Who can do this step matched automatically
    ✓ ISO 9001 500 m3
    “Technology: microbial fermentation with ~500 m3 fermentation capacity; 15+ patents; developed/upscaled probiotic production technologies.”
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “TideMotion® Bioreactors”
    CHITOSE Japan
    industrial scale
    “AI x BIOMANUFACTURING”
    ✓ ISO 9001 600 tons pilot scale
    “Bota Biosciences is a global leader in Physical AI-driven biomanufacturing, dedicated to making biotechnology a reliable and scalable engine of productivity.”
    150 m3/month
    “We have set up a state of art laboratory at our plant including Auto Fermentor’s, Bio- digesters, Spray Driers, Aseptic blenders & computerized auto lines etc.”
  4. 4
    Growth detection
    Visual turbidity inspection, automated colony imaging, or a metabolic-activity signal indicates the presence or absence of viable microorganisms in the sample.
  5. 5
    Result confirmation
    Imaging or growth-curve software confirms any detected signal meets the assay’s positive criteria, ruling out artifacts before a formal sterile/non-sterile determination.
  6. 6
    Batch release decisionTesting & analytics

    The confirmed result is compared against the product’s validated sterility specification, driving the batch-release or batch-rejection decision with a documented, auditable record.


    Who can do this step matched automatically
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and …”
    ✓ ISO 9001 industrial scale
    “As a contract research organization (CRO), we provide smart, rapid, and effective solutions using cutting-edge technologies to drive customer success.”

4 · Who delivers

Matched suppliers (matched automatically)

SartoriusGermanyProduceractive
Bota Bio 恩和生物ChinaProduceractive
ImperagenUnited KingdomEquipmentactive
SynCTI (Singapore)SingaporeResearch / RTOactive
MicroHarvest GmbHGermanyProduceractive
OrvionNetherlandsResearch / RTOactive
MENA-WaterUnited Arab EmiratesProduceractive

In the services and supply catalogue 3 · paid service

Analytical & testing services · Laboratory & analytical instruments · Spare parts, service & calibration

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Merck Millipore🇩🇪 GermanySteritest SymbioConfigurable peristaltic pump systems for classical membrane filtrationCommercial
Charles River Laboratories🇺🇸 USACelsis RMMRapid microbial detection accelerating bioburden/sterility resultsCommercial
bioMérieux🇫🇷 FranceBacT/ALERT 3DClinical-microbiology-derived automated continuous microbial detectionCommercial
Sartorius🇩🇪 GermanySterisart Universal (Gen 4)Connected-lab digital pump for compliance and data captureCommercial
Rapid Micro Biosystems🇺🇸 USAGrowth DirectAutomated colony imaging validated against comprehensive organism panelsCommercial, public (NASDAQ:RPID)

5 · Rules & route to market

Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

The US hosts both a legacy rapid-microbial-detection pioneer and a newer automated- colony-detection specialist, giving American biopharma the deepest bench of alternatives to the classical 14-day method.

rapid microbial detection commercialization, automated colony imaging, RMM validation science#

  • Charles River Laboratories: the Celsis rapid microbial detection (RMM) platform accelerates bioburden and sterility results versus the days-long wait of traditional compendial methodology, positioned to reduce batch-release delays and costs in both pharmaceutical and cosmetic production.
  • Rapid Micro Biosystems: the Growth Direct platform automates colony detection for rapid sterility testing, validated against a comprehensive organism panel under USP <1223>, Ph. Eur. 5.1.6 and PDA Technical Report 33 to demonstrate detection capability equivalent to classical methods.

European Union

Germany contributes both halves of the classical membrane-filtration pump market, while France’s bioMérieux brings a distinct continuous-monitoring architecture adapted from clinical microbiology.

membrane-filtration pump systems, connected-lab compliance, clinical-microbiology-derived detection#

  • Merck Millipore (Merck KGaA, Germany): the Steritest Symbio peristaltic pump platform configures to fit varied sample types, packaging and controlled testing environments, with a range of devices, pumps and sterile media supporting the classical 14-day test.
  • Sartorius (Germany): the Sterisart Universal pump, now in its fourth generation, is positioned as a next-generation sterility-testing pump for the “connected lab,” emphasizing both convenience and compliance for digitally integrated QC workflows.
  • bioMérieux (France): the BacT/ALERT 3D system, adapted from clinical blood-culture microbial detection technology, provides automated, continuous microbial detection for pharmaceutical sterility and rapid product-safety testing.

China

No China-headquartered sterility-testing vendor cleared this screening round with confirmed, on-domain evidence; demand is driven by China’s expanding parenteral drug and biologics manufacturing base, currently served largely through the global vendors' regional distribution and applications-support networks.

import-dependent instrumentation, domestic parenteral-manufacturing demand, distributor-served market#

  • Global vendor distribution: Merck Millipore, Charles River, bioMérieux, Sartorius and Rapid Micro Biosystems each maintain China sales and applications-support organizations serving domestic parenteral-drug and biologics manufacturers.
  • Domestic manufacturing build-out: China’s growing injectable-drug and biologics production base is the main demand driver for sterility testing, without a confirmed domestic instrument originator identified in this screen.
  • Screening note: two candidate China-headquartered vendors were probed and neither returned confirming, on-domain evidence this round — not asserted as absent, only as unconfirmed.

6 · Money: tenders & grants

GrantEmpowering local urban food systems entrepreneurship and innovation
European Commission · EU
Sep 23, 2027
304 days
GrantFostering common farmland birds and mammals for resilient food production systems
European Commission · EU
Sep 22, 2027
303 days
GrantTowards commercialization of food systems microbiome solutions
European Commission · EU
Sep 23, 2027
304 days
GrantAutomated Scientific Discovery – Food (RAISE pilot)
European Commission · EU
Feb 2, 2027
71 days
GrantCapacity building for extending product lifecycles through repair and refurbishment
European Commission · EU
Sep 22, 2027
303 days

7 · Tech stack & innovations

The stack layers aseptic sample handling, incubation, and growth-detection technology on a common software backbone, with the choice between classical and rapid methods driven by whether release speed or established compendial precedent takes priority.

  1. Automated membrane-filtration pump systems:
    • Peristaltic pumps automate the aseptic filtration and post-filtration rinse steps of the classical sterility test, configurable to different sample containers and packaging formats.
    • Installation inside an isolator or RABS reduces environmental false-positive risk during the aseptic manipulation itself.
  2. Automated colony detection and imaging:
    • Continuous imaging of growth media flags colonies as they form during incubation, rather than waiting for a single manual end-point read at day 14.
    • Detection sensitivity is validated against a standardized panel of compendial and environmental organisms to demonstrate equivalence to the classical method before regulatory acceptance.
  3. Clinical-microbiology-derived continuous monitoring:
    • Platforms originally built for clinical blood-culture microbial detection are adapted to continuously monitor pharmaceutical samples for growth signals, leveraging technology validated at high throughput in a different regulated application.
    • Automated, continuous monitoring reduces the manual visual-inspection burden of the classical 14-day incubation period.

Sources 5 · 0 independent · 5 producer sites

Producers' own sites 5

  1. Merck kgaa producer checked 2026-02-25 · link not kept
  2. Charles river producer checked 2026-04-24 · link not kept
  3. Biomerieux producer checked 2026-07-18 · link not kept
  4. Sartorius producer checked 2025-11-11 · link not kept
  5. Rapid micro biosystems producer checked 2026-08-07 · link not kept